
Web Release Date: January 22,
Biologically Active Compounds from Aphyllophorales (Polypore) Fungi
Department of Pharmacognosy and National Center for Natural Product Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, Mississippi 38677-1848
Received August 14, 2003
Abstract:
This review describes biologically active natural products isolated from Aphyllophorales, many of which are known as polypores. Polypores are a large group of terrestrial fungi of the phylum Basdiomycota (basidiomycetes), and they along with certain Ascomycota are a major source of pharmacologically active substances. There are about 25 000 species of basidiomycetes, of which about 500 are members of the Aphyllophorales, a polyphyletic group that contains the polypores. Many of these fungi have circumboreal distributions in North America, Europe, and Asia and broad distributions on all inhabited continents and Africa; only a small number of the most common species with the most obvious fruiting bodies (basidiocarps) have been evaluated for biological activity. An estimated 75% of polypore fungi that have been tested show strong antimicrobial activity, and these may constitute a good source for developing new antibiotics. Numerous compounds from these fungi also display antiviral, cytotoxic, and/or antineoplastic activities. Additional important components of this vast arsenal of compounds are polysaccharides derived from the fungal cell walls. These compounds have attracted significant attention in recent years because of their immunomodulatory activities, resulting in antitumor effects. These high molecular weight compounds, often called biological response modifiers (BRM), or immunopotentiators, prevent carcinogenesis, show direct anticancer effects, and prevent tumor metastasis. Some of the protein-bound polysaccharides from polypores and other basidiomycetes have found their way to the market in Japan as anticancer drugs. Finally, numerous compounds with cardiovascular, phytotoxic, immunomodulatory, analgesic, antidiabetic, antioxidant, insecticidal, and nematocidal activities, isolated from polypores, are also presented. In fact many of the fungi mentioned in this paper have long been used in herbal medicine, including polypores such as Ganoderma lucidum (Reishi or Ling Zhi), Laetiporus sulphureus (Chicken-of-the-Woods), Trametes versicolor (Yun Zhi), Grifola umbellata (Zhu Lin), Inonotus obliquus (Chaga), and Wolfiporia cocos (Hoelen).
Polypores and corticioid fungi are members of the Aphyllophorales, a group of morphologically complex, terrestrial basidiomycetes. A phylogenetic classification for these fungi is under development, but the groups are probably not monophyletic.1 As a result of updates in nomenclature and systematics information over the last thirty years, escalating even more from DNA sequence analyses, there are numerous changes in the names of these fungi to reflect the phylogenetic situation. This causes a problem in evaluating the older literature and in comparing studies of the same fungus that has been known by one or more different names. The fungal names used in this paper generally follow those of Gilbertson and Ryvarden or other recent monographic materials.2
Many of these fungi are saprobic wood decayers, and as such, these fungi are most often found on logs, stumps, or other dead wood. Many polypores are typically tough and woody and produce basidiospores on walls of tubes of the undersurface hymenophore (the tissue that bears the fertile layer). Common names for the fruiting bodies or basidiocarps of polypores include conks, shelf, and bracket fungi. Some basidiocarps are perennial, and others often do not rot readily; they may remain undecayed to the point that algae or mosses begin to grow on their surfaces. As mentioned above, the majority of polypores absorb nutrients from the dead woody plant parts and as such are saprobic. These may include polypores that grow on living trees and cause decay of the nonfunctional heartwood. A few of these fungi invade conducting plant tissues and a parasite, and as such are parasites; a few others are mycorrhizal and exchange nutrients and carbon with the roots of plants.
Several excellent review articles have been published on
the subject of biologically active secondary metabolites from
basidiomycetes.3-13
According to a recent biological evaluation of over 200 mushroom species, more than 75% of screened polypores showed strong antimicrobial activity.14 These activities are associated not only with small molecule secondary metabolites but also with high molecular weight cell wall polysaccharides. The major philosophy of the search for antimicrobial compounds from basidiomycetes is that humans (and animals) share common microbial pathogens with fungi, such as Escherichia coli, Staphylococcus aureus, and Pseudomonas areuginosa, so that we can benefit from defensive strategies used by fungi against microorganisms. No wonder so many antibiotics have been derived from fungi.
Basidiomycetes, especially polypores, have a long history of medicinal use. For instance, the tinder polypore, Fomes fomentarius, was used in the 18th and 19th centuries in hemostatic dressings and bandages.15 The same polypore together with the birch polypore (Piptoporus betulinus), which has had a variety of medicinal and other uses, was found with the body of the famous 5300 year old "Ice Man" in a glacier of Italian Alps in 1991. It is not known, however, how he used either of these fungi.4,16
There are numerous publications describing antimicrobial properties of secondary metabolites isolated from
various polypores.17-39
For example, two secondary metabolites, ganomycin A (1) and ganomycin B (2), isolated from G. pfeifferi showed moderate growth inhibition of several bacterial strains, particularly Gram-positive strains such as B. subtilis, S. aureus, and Micrococcus flavus.17
The antifungal isocoumarin oospolactone (3) was identified as a secondary metabolite of Gleophyllum sepiarium.18
This compound was most active against strains of the
asexual ascomycete Alternaria, showing MIC values of
12.5-25
g/mL.
Another group of antimicrobial metabolites of polyketide origin are merulinic acids A, B, and C (4-6) isolated from the fruiting bodies of the polypores Merulius tremellosus and Phlebia radiata.19
The merulinic acids showed antimicrobial activity with
MIC values of 0.4-10
g/mL, particularly against Arthrobacter citreus, B. subtilis, Corynobacterium insidiosum,
Micrococcus roseus, and Sarcina lutea. Mycobacterium phlei
was selectively inhibited by 5 and 6, while 4 was inactive.
Similarly, S. aureus and Proteus vulgaris were inhibited
only by merulinic acid B (5). It is interesting that mycelial
cultures of Merulius tremellosus do not produce merulinic
acids, but instead a highly antifungal sesquiterpenoid,
merulidial (7).19 This occurrence serves as an example of
the influence of different life cycle stages on the production
of fungal secondary metabolites.
Biological activities of merulidial (7) are associated with the presence of two aldehyde functions in the molecule. The triol obtained by the reduction of merulidial is inactive.20
Antimicrobial sesquiterpenes, desoxyhypnophilin (8), hypnophilin (9), 6,7-epoxy-4(15)-hirsutene-5-ol (10), and 6,7-epoxy-4(15)-hirsutene-1,5-diol (11), with a hirsutane skeleton were isolated from the wood-decaying polypore Lentinus crinitus.21
Desoxyhypnophilin (8) and hypnophilin (9) are active
against the Gram-positive bacterium Bacillus cereus, and
spores of Aspergillus niger, Aspergillus flavus, and Mucor
rouxii with MIC values of 1-5
g/mL. The
,
-unsaturated
exomethylene ketone system, present in these compounds,
is responsible for antimicrobial activity. Reduction of the
carbonyl group in 8 leads to a significant drop in antimicrobial activity of 10.21 Hypnophilin (9) together with
pleurotellol (12) and pleurotellic acid (13) also were isolated
from fermentation of the gilled mushroom Pleurotellus
hypnophilus (Agaricaceae).22 Hypnophilin (9) and pleurotellol (12) act in addition as the plant growth inhibitors.12
Two other hirsutane derivatives, hirsutic acid (14) and
complicatic acid (15), were isolated from the wood-decaying
polypore Stereum complicatum.23 Similar to other hirsutanes with an
,
-unsaturated exomethylene ketone system, complicatic acid (15) showed moderate antimicrobial
activity against S. aureus.24
Another antimicrobial hirsutane sesquiterpene, coriolin
(16), was isolated from the white-rot basidiomycete Coriolus consors.25 Coriolin is active against S. aureus, M. flavus,
B. subtilis, and B. anthracis with the same MIC values of
12.5
g/mL. A closely related compound isolated from the
same fungus, coriolin B (17), did not show any antimicrobial activity, but its synthetic derivative, diketocoriolin B
(18), obtained by oxidation of coriolin B (17) showed
antimicrobial activity similar to that of coriolin (16).26
A potent antifungal sesterterpene
-D-xyloside, aleurodiscal (19), was isolated from another wood-rotting polypore, Aleurodiscus mirabilis.27 Aleurodiscal (19) is selectively active against zygomycetes, especially against Mucor
miehei.
Ganoderma applanatum, known commonly as the artist's conk, provides the sterols 5
-ergost-7-en-3
-ol (20), 5
-ergost-7,22-dien-3
-ol (21), 5,8-epidioxy-5
,8
-ergost-6,22-dien-3
-ol (22), and a novel lanostanoid (23) that are active
predominantly against Gram-positive bacteria.28
Several lanostanoid derivatives, polyporenic acid C (24),
3
-acetyloxylanosta-8,24-dien-21-oic acid (25), pinicolic acid
A (26), trametenolic acid B (27), and fomitopsic acid (28),
isolated from the polypore Fomitopsis pinicola have shown
antimicrobial activity against B. subtilis in a TLC-bioautography assay in quantities from 0.01 to 1
g, but did not
inhibit B. subtilis in a classic agar dilution assay at
concentrations up to 50
g/mL.29
A culture of an Ethiopian Favolaschia species produced favolon (29), an unusual ergosterone with a B/C-cis ring junction. This compound displayed strong antifungal activity against numerous fungal pathogens, with the strongest inhibitions in the agar diffusion assay for Mucor miehei, Paecilomyces varioti, and Penicillium islandicum.30
Basidiocarps of the genera of Agaricus, Favolaschia, and
Filoboletus produced strobilurins A (30), E (31), and F1
(32), 9-methoxystrobilurin A (33), and oudemansin A (34),
aromatic antifungal compounds derived by way of the
shikimic acid pathway. These compounds exhibited potent
antifungal activity (MIC values of 0.1-1
g/mL), but they
had no discernible antibacterial properties.
The strobilurins and oudemansins also inhibited the growth of a number of fungal plant pathogens at very low concentrations.12 They have a unique mode of action, selectively inhibiting the respiration of fungi by interfering with the ubiquinol oxidation center of the mitochondrial bc1 complex.12 These compounds have served as natural product prototypes for the design and development of synthetic analogues. Their lack of mammalian toxicity has made them good lead compounds for the development of commercial agricultural fungicides.31
Very simple aromatic compounds, such as anisaldehyde (35) and (4-methoxyphenyl)-1,2-propanediol (36), showing weak antifungal activity, were isolated from Pleurotus pulmonarius and Bjerkandera adusta.32
One of the first antimicrobial compounds ever isolated from a polypore was biformin (37), a polyacetylenic carbinol. Biformin (37) is produced by Trichaptum biforme (as Polyporus biformis) and is active against a wide variety of bacteria and fungi.33
The aromatic acetylene derivatives frustulosin (38) and frustulosinol (39) isolated from the liquid cultures of Stereum frustulosum were active against several bacteria such as S. aureus, Bacillus mycoides, and B. subtilis and also moderately active against Vibrio cholera and V. cholera phage.34,35
Another example of an acetylenic compound exhibiting antifungal activity is the 1-hydroxy-2-nonyn-3-one (40) isolated from the fermentation of the polypore Ischnoderma benzoinum.36
The red polypore Pycnoporus sanguineus produces cinnabarin (41), a phenoxazinone with antimicrobial activity.
B. cereus and Leuconostoc plantarum were the most sensitive to cinnabarin, each being inhibited with an MIC value
of 62.5
g/mL.37,38
A large group of antimicrobial secondary metabolites isolated from polypores also includes a cyclodepsipeptide, beauvericin (42). Beauvericin (42) is produced by the bright yellow polypore Laetiporous sulphureus (as Polyporus sulphureus), commonly known as "Chicken-of-the-Woods".39 Beauvericin also is considered as a mycotoxin produced by hypocrealean ascomycetes in grain.40
A number of polypores exhibit immunoprotective activity and provide protection against a variety of infectious diseases. This kind of activity is associated mainly with the presence of polysaccharides. PSK, a protein-bound polysaccharide isolated from Trametes versicolor (as Coriolus versicolor), was found to increase resistance in mice against infection with Listeria monocytogenes by enhancing oxygen metabolism of the host macrophages.41
In their excellent review article on mushroom antivirals, Brandt and Piraino divided the antiviral compounds
from fungi into two major classes: (i) those that act indirectly as biological response modifiers (usually from polysaccharide fractions); and (ii) those that act directly as viral
inhibitors.8 In polypores, however, several polysaccharide
fractions display direct inhibitory effects on various viruses.
The polysaccharide preparation, PSK from T. versicolor (as
C. versicolor), commonly known as turkey tail, was found
to have an antiviral effect on human immunodeficiency
virus (HIV) in vitro.42,43
In contrast with PSK, another protein-bound polysaccharide, PSP, isolated from T. versicolor (as C. versicolor),
is not a "true" antiviral and acts indirectly by immunostimulation.8 PSP was reported to inhibit the binding of
HIV-1 gp120 to immobilized CD4 receptor with an IC50
value of 150
g/mL and recombinant HIV-1 reverse transcriptase with an IC50 of 6.25
g/mL.46 Both the polysaccharides PSK and PSP are heteroglucans with
-(1
4)-
and
-(1
3)glucosidic linkages, with a protein or polypeptide component. The presence of fucose in PSK and rhamnose and arabinose in PSP distinguishes the two protein-bound polysaccharides, which are otherwise chemically
similar.47
Water-soluble preparations from carpophores of Ganoderma applanatum (as Elfvingia applanata) exhibited potent antiviral activity against vesicular stomatitis virus Indiana serotype VSV (IND).48
Aqueous extracts from four polypores, Fomitella supina, Phellinus rhabarbarinus, Trichaptum perrottotti, and Trametes cubensis, showed strong anti-HIV-1 activity without toxicity toward lymphocytic cells. It was demonstrated that the active compounds of these extracts act by a mechanism of direct virion inactivation and inhibition of syncytium formation in an in vitro culture system.49
Water-soluble lignins isolated from the sclerotia of the
polypore Inonotus obliquus, commonly known as "Chaga",
inhibited HIV protease with an IC50 value of 2.5
g/mL.50
Recently, two phenolic compounds, hispolon (43) and hispidin (44), isolated from the basidiocarps of Inonotus hispidus showed considerable antiviral activity against influenza viruses type A and B.51
The filtrate from the culture of polypore Fomes fomentarius, "tinder conk", is highly active against the mechanical transmission of tobacco mosaic virus (TMV) with an
IC50 value of 10
g/mL, and it has similar effects against
the TMV infection on bell pepper and tomato plants.52
The fruiting bodies of Ganoderma lucidum are the source
of antiviral triterpenoids. Ganoderic acid
(45) isolated
from the spores of G. lucidum showed significant anti-HIV-1 protease activity, with an IC50 value of 20
M.53 The
same species also produced ganoderiol F (46) and ganodermanontriol (47), which have anti-HIV-1 activity.54
Recently, antiviral triterpenes also were isolated from the European polypore Ganoderma pfeiferri. Ganodermadiol (48), lucidadiol (49), and applanoxidic acid (50) showed antiviral activity against influenza virus type A and HSV-1.55
The cytotoxic, antineoplastic, and immunomodulatory
activities of polypore extracts are mostly associated with
the presence of polysaccharides, although numerous smaller
molecular weight cytotoxic polypore metabolites also are
known.56,57
g/mL as well as against promyelocytic human leukemia
HL60 cells at 5
g/mL.
Extraction of Laetiporus sulphureus var. miniatus provided several secondary metabolites, among which compounds such as egonol (52), demethoxyegonol (53), and
egonol glucoside (54) showed low cytotoxicity against Kato
III cells with IC50 values of 28.8, 27.5, and 24.9
g/mL,
respectively.59
Two highly oxygenated phenols, fomecin A (55) and B
(56), were isolated from the polypore Pyrofomes demidoffii
(as Fomes juniperinus).60 Fomecin B is cytotoxic against
HeLa, MDCK, and FL cells with IC50 values of 20, 14, and
17
g/mL, respectively.61
The semisynthetic analogue of coriolin B (17) mentioned
above, the antimicrobial diketocoriolin B (18), also exhibited antitumor activity.62,63
g/mL, respectively.21
The effective antifungal metabolites from Merulius
tremellosus, merulidial (7) and its co-isolates tremediol (57),
tremetriol (58), and
-bisabolol (59), were shown to be
cytotoxic. Merulidial inhibits DNA synthesis in ECA cells
at a concentration of 9
g/mL and is also mutagenic.20
Three other compounds (57-59) induce apoptosis in human
promyelocytic leukemia cells HL-60 and interfere with
signal transduction in COS-7 cells.12
A basidiocarp reported as a species of Panus contained
two caryophyllane sesquiterpenes, naematolon (60) and
naematolin (61).64 The cytotoxicity of these compounds is
probably associated with the presence of an
,
-unsaturated keto system in their structures. Naematolon (60),
possessing two such systems, is about 5 times more
cytotoxic than naematolin. Naematolon inhibits the incorporation of thymidine into the DNA of ECA cells with an
IC50 value of 2
g/mL. It did not, however, show any
significant antitumor activity in vivo with P-388 lymphocytic leukemia, Lewis lung carcinoma, or B-16 melanocarcinoma. The LD50 in mice was determined as high as 225
mg/kg of body weight.12
The crude drug "Chorei", prepared from the dried fruit
body of Polyporus umbellatus, is known in Japan and the
People's Republic of China as a remedy for kidney and
other diseases. Seven new ecdysterone analogues, polyporusterones A-G (62-68), were isolated from the extract of
this polypore. All of these showed cytotoxic activity against
leukemia L-1210 cells with IC50 values of 10-64
g/mL.65
The crude extract of the European wood-rotting fungus
Trametes versicolor (as Polyporus versicolor) contains cytotoxic, polyoxygenated ergosterol derivatives. The active
compounds 3
,5
,9
-trihydroxyergosta-7,22-dien-6-one (69)
and 3
,5
,9
-trihydroxy-6
-methoxyergosta-7,22-diene (70)
were isolated by bioassay-guided fractionation using rat
hepatoma cells.66
The polypore Antrodia cinnamomea, a parasite of the heartwood of the Taiwanese evergreen tree Cinnamomum micranthum, has been utilized in Chinese medicine for the treatment of various disorders including liver cancer. Bioassay-guided fractionation of this polypore provided three new steroids, zhankuic acids A-C (71-73).
Biological study revealed that zhankuic acid A (71)
exhibits cytotoxic activity against P-388 murine leukemia
cells with an IC50 value of 1.8
g/mL.67
Numerous cytotoxic triterpenoids have been isolated from various species of the Polyporaceae. An excellent review of their structures was published several years ago by Mizuno and his colleagues.57 Just two polypores, Ganoderma lucidum and G. applanatum, provided 113 lanostane derivatives, and their isolation and biological activities were the subject of 35 publications. Moreover, 47 triterpenoids were isolated from yet other polypores including species reported in the genera Trametes, Fomes, Polyporus, Coriolus, Laetiporus, Fomitopsis, Piptoporus, Poria, and Cryptoporus, and accounted for another 35 publications. This review will not describe those compounds, and the reader is referred to Mizuno's paper for detailed information.57
Ganoderma lucidum is well known in Korea, Japan, the
People's Republic of China, and other countries in eastern
Asia, where it is used as a folk remedy for the treatment
of such disparate conditions as cancer, hepatitis, chronic
bronchitis, asthma, hemorrhoids, and fatigue symptoms.68
After providing over 130 pharmacologically active triterpenoids, there are yet additional new triterpenes isolated
from this polypore and published in the recent literature.69,70
M, respectively.69
Lucialdehydes A-C (76-78), three new lanostane-type
triterpene aldehydes, also were isolated from G. lucidum.
The most active of these compounds, lucialdehyde C (78),
was found to be cytotoxic against murine sarcoma Meth
A, sarcoma S-180, human breast cancer T-47D, and Lewis
lung carcinoma LLC cells with ED50 values of 3.8, 7.1, 4.7,
and 10.7
g/mL, respectively.70
Recently, two new 3,4-secolanostane-type triterpenes were isolated from the sclerotium of Poria cocos.71 These two new compounds, poricoic acid G (79) and poricoic acid H (80), showed potent inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) activation induced by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). Poricoic acid G (79) was found to be significantly cytotoxic to leukemia HL-60 cells with a GI50 (concentration that yields 50% growth of cancer cells) value of 39.3 nM, with only moderate cytotoxicity to the other cells.
The use of hot water extracts of medicinally important basidiomycetes as a remedy against cancer is known in the folk medicine of many countries. This kind of therapy was used for centuries in Korea, Japan, the People's Republic of China, Russia, and other eastern countries. Most of the pharmacologically active, anticancer basidiomycetes belong mainly to the Polyporaceae. The water extracts of those basidiocarps contain predominantly polysaccharides, which are the principal components of the fungal cell walls. These polysaccharides have attracted significant attention in recent years due mainly to their immunomodulatory activity, which results in their antitumor effects. These high molecular weight compounds often are called biological response modifiers (BRM), or immunopotentiators, which are able to prevent carcinogenesis and carcinostasis. Several excellent review articles about the isolation, biological activity, and development of antitumor-active polysaccharides were published in the late 1990s.9,10,56,57
The first written reports (Compendium of Materia Medica) associated with the medicinal value of polypore mushrooms date back to Eastern Han Dynasty (25-220 AD) in
China.72 Modern research with polypore polysaccharides
can be said to have started in 1969 in Japan with the work
of Ikegawa, who reported a marked host-mediated antitumor activity of hot water extracts of numerous edible
polypores with Sarcoma 180 grafted on Swiss albino mice.73
Since that time, numerous publications have appeared on
the isolation and characterization of anticancer polysaccharides. The majority of these compounds can be classified
as
-D-glucans, i.e., polysaccharides yielding only D-glucose
after acid hydrolysis.57 In addition, a number of other
polymeric compounds such as heteropolysaccharides, glycoproteins and glycopeptides, chitin derivatives, lectins,
RNA, and indigestible polysaccharides (dietary fibers) were
isolated from polypores.
The vast majority of antitumor
-D-glucans isolated from
polypores are
-(1
3)-D-glucopyranans with 500 000-2 000 000 mean molecular weight and characteristic
-(1
6)-D-glucosyl branches (81). The level of their activity is closely
related to their molecular weight, branching, and solubility
in water. Among these preparations, higher antitumor activity is correlated with the higher molecular weight, lower
level of branching, and greater water solubility of
-glucans.74
Relatively large quantities of
-glucans can be obtained
from basidiocarps by extraction with dilute alkali, but in
this case the product is insoluble in water.75 Attempts have
been made to increase
-glucan solubility in water by chemical modifications such as hydroxymethylation, carboxymethylation, periodic acid oxidation followed by sodium
borohydride reduction, lowering (1
6) branching by mild
Smith degradation, and partial conversion of glucopyranosyl residues in the main chain of
-glucans to corresponding
3,6-anhydro derivatives or other sugar residues.10,75-77
The structures of the
-glucans have been elucidated by
NMR and X-ray crystallography and a combination of
chemical methods such as methylation, periodic acid oxidation, Smith degradation, and enzymatic hydrolysis.78,79
-glucans have a secondary structure of a right triple-stranded helix.80 High-resolution solid state 13CNMR spectroscopy detects at least three types of secondary structures
of
-D-glucans: single-chain, single-helix, and triple-helix
forms.57 The first two correspond to anhydrous and hydrated forms and are readily interconvertible by hydration
and dehydration. The third one, the triple-helix form, is
associated with the presence of an annealed gel form of
-D-glucan.81 According to conformation-activity relationship studies, the single-helical
-D-glucans are more effective as antitumor agents as compared to triple-helical ones,
although this distinction is less clear for branched glucans.82
One of the examples of antitumor
-D-glucans from polypores is compound D-II isolated from the cultured mycelium of Trametes versicolor (as Coriolus versicolor). D-II
strongly inhibited the growth of Sarcoma-180 transplanted
subcutaneously in mice by intraperitoneal, intravenous,
subcutaneous, and intramuscular administration at a dose
of 5 mg/mL. The molecular weight of D-II was estimated
as 2 000 000 by gel filtration or 6 500 000 by light-scattering analysis. The chemical structure of D-II was elucidated
by a combination of oxidation, methylation, and degradation methods as a
-(1
3)-D-glucan in which one of every
three glucose residues is branched at C-6 with a
-D-(1
6)-linkage.83
The polysaccharide fraction of polypore fungal extracts
also may contain
-D-glucans with heterosaccharide residues, i.e., xylose, galactose, mannose, glucuronic acid, and
other sugars, as well as glycopeptides or glycoproteins.
Various antitumor-active heteroglucans and their protein
complexes were isolated from the polypore Ganoderma lucidum (Reishi mushroom) including glucuronoglucan, xyloglucan, mannoglucan, xylomannoglucan, and other compounds.10,57 The hot-water extract of Albatrellus confluens
(as Polyporus confluens) also provides xyloglucan-protein
complexes with strong antitumor activity.84,85
One of the most well-studied antitumor polysaccharide from polypores is PSK, also known as Krestin. PSK, isolated from Trametes versicolor (as Coriolus versicolor), is a protein-bound polysaccharide or glycoprotein that is effective against several animal cancer models.87 Oral administration of PSK enhances the antitumor cytotoxicity of hepatic lymphocytes, preventing liver metastasis through the augmentation of organ-associated natural killer activity.88 It also expresses superoxide dismutase mimicking activity and enhances in vitro anticancer activity of the known anticancer drug cisplatin.89 PSK suppresses pulmonary metastasis of methylcholanthrene-induced sarcomas, human prostate cancer DU145M, and lymphatic metastasis of mouse leukemia P388, and it has prolonged the survival period in spontaneous metastasis models. PSK also suppresses the metastasis of rat hepatoma AH60C, mouse colon cancer colon 26, and mouse leukemia RL male 1 in artificial metastasis models.90 PSK (Krestin) is currently marketed in Japan as an immunotherapeutic agent for colorectal, gastric, and lung cancers. In an excellent review on antitumor-active polysaccharides from medicinal basidiomycetes, Mizuno et al.56 give an extensive overview of antitumor properties of polysaccharides isolated from various polypores.
An Australian polypore species of Panus biosynthesizes
the drimane sesquiterpene panudial (82). This compound,
with an A/B ring cis junction, is isomeric with kuehneromycin B (83), isolated from other fungi in addition to
polypores. Panudial (82) is a potent inhibitor of bovine and
human ADP-stimulated platelet aggregation, with IC30
values of 2.5 and 6
g/mL, respectively.64
An ergostane derivative (84) isolated from Grifola umbellata (as Polyporus umbellatus) was found to inhibit rabbit platelet aggregation induced by collagen or ADP in vitro.91
The inhibitory effects on platelet responses to various aggregating agonists were also observed for ganodermic acid S (85), a triterpenoid isolated from the polypore Ganoderma lucidum. Ganodermic acid S potentiated the response of human gel-filtered platelets to prostaglandin PGE-1 and inhibited the platelet response to collagen.92
Several secondary metabolites from polypores show phytotoxic activity.12 A parasite of conifers, the polypore Heterobasidium annosum (previously known as Fomes annosus), produces phytotoxic bicyclic sesquiterpenes, fomannosin (86) and fomannoxin (87). Both compounds are toxic to the green alga Chlorella pyrenoidosa.93
The above-mentioned hypnophilin (9) and pluerotellol (12) are phytotoxic. They inhibited indole-3-acetic acid-induced growth in the classic experiment using the Avena (oat) coleoptile bioassay.22
A prenylated shikimic acid derivative panepoxydone (88),
isolated from the fermentation of cultured mycelia of Panus
conchatus, Panus rudis, and Lentinus crinitus, was found
to inhibit NF-
B-mediated signal transduction in African
green monkey COS-7 cells.12,94 Panepoxydone inhibited the
NF-
B-activated expression of the reporter gene secreted
alkaline phosphatase (SEAP) with an IC50 value of 1.5-2.0
g/mL.95
Some secondary metabolites from polypores are also
known as enzyme inhibitors. Caloporoside (89) isolated
from Caloporus dichrous inhibits pig's brain phospholipase
C with a Ki value of 10
g/mL.96
As already mentioned above, diketocoriolin (18) exhibited immunomodulatory effects most probably by inhibition of Na+-K+-ATPase.97
A highly oxygenated metabolite, cyclophellitol (90),
isolated from Phelinus spp., specifically inhibited almond
-glucosidase with an IC50 value of 0.8
g/mL.98 Another
metabolite from Tyromyces lacteus, tyromycin A (91),
specifically inhibited leucine and cysteine aminopeptidases
of HeLa S3 cells.99
Scutigeral (92), a secondary metabolite isolated from
fruiting bodies of Albatrellus ovinus, has affinity to the
brain dopamine D1 receptors, stimulates rat dorsal root
ganglion neurons, and may act as an orally active painkiller
targeting vanilloid receptors (VR1).100,101
M.102
As mentioned earlier, Laetiloporus sulphureus, Chicken-of-the-Woods, well known for its spectacular size, color, and
shape, was reported to cause visual hallucinations and
ataxia in children upon ingestion.103 Two triterpenoids,
15
-hydroxytrametenolic acid (94) and sulfurenic acid (95),
isolated from this mushroom showed dopamine D2 receptor
agonistic activity in monkeys by intramuscular injection
at a dose of 3.8 mg/kg/body weight.102
Dehydrotrametenolic acid (96) has been found in several polypores including Wolfiporia cocos, Poria carbonica, Fomitopsis officinalis (as Fomes officinalis), Laetiloporus sulphureus (as Laetiporus versiporus), and Antrodia cinnamomea. Dehydrotrametenolic acid (96) reduces hyperglycemia in mice with noninsulin-dependent diabetes mellitus (NIDDM) and acts as an insulin sensitizer in glucose tolerance tests.104
Two lipid peroxidation inhibitors, betulinans A (97) and
B (98), were isolated from the methanol extract of Lenzites
betulina.105 Peroxidative damage of cells and organellar
membranes by free radicals has been implicated in pathogenesis of various diseases such as atherosclerosis, arthritis, myocardial ischemia, and cancer. Betulinans A (97) and
B (98) inhibited lipid peroxidation with IC50 values of
0.46 and 2.88
g/mL, respectively. Betulinan A (97) was
about 4 times more active as a radical scavenger than
vitamin E.
An extract obtained from a tissue culture (i.e., mycelium)
of the fruiting body of Stereum hirsutum also produced
antioxidant metabolites, sterin A (99) and sterin B (100).106
In the lipid peroxidation inhibition test using rat liver
microsomes, sterin A (99) showed inhibition with an IC50
value of 8
g/mL.
The inedible fruiting body of Cryptoporus volvatus (Polypopraceae) contains large amounts of the novel drimane
sesquiterpenoids cryptoporic acids A-G (101-107). The
intensely bitter tasting cryptoporic acids completely inhibited germination of rice in husk and elongation of the
second coleoptile at a concentration of 200 ppm. Their main
activity, however, was the strong inhibition of superoxide
anion radical (SAR) release. Inhibitors of SAR release and
radical scavengers are necessary to prevent human diseases caused by ischemia and inflammation. Cryptoporic
acids inhibit the release of SAR from guinea pig peritoneal
macrophages induced by the SAR stimulant formyl-methionyl-leucyl-phenylalanine (FMLP) at concentrations
from 0.05 to 25
g/mL.107
Cryptoporic acid E (105) inhibited the tumor promotion activity of okadaic acid in two-stage carcinogenesis experiments. The antitumorigenic effect of 105 on colon carcinogenesis also was observed.107
Some secondary metabolites isolated from polypores have insecticidal and nematocidal activity. Examples include beauvericin (42), already mentioned above, from Laetiloporus sulphureus (as Polyporus sulphureus), as well as several ascomycetes that exhibit significant insecticidal activites,40 or anisalaldehyde (35) and (4-methoxyphenyl)-1,2-propandiol (36), with nematocidal properties.108 Nematocidal activities against Aphelencoides besseyi also have been reported for two alkylated furaldehydes, 5-pentyl-2-furaldehyde (108) and 5-(4-pentenyl)-2-furaldehyde (109) isolated from Irpex lacteus.109
Polypore fungi are the major source of biologically active natural products among the species of the diverse fungal phylum Basidomycota. They provide a rich variety of active secondary metabolites and polysaccharides. Over and over certain polypores have been found to contain active compounds. These include Trametes versicolor, Laetiporus sulphureus, and several species of Ganoderma, with long-lived fruiting bodies that ideally resist decay during their relatively long periods (weeks to months) of active basidiospore production. This is evident from the large number of compounds isolated from polypores that have proved to have significant antimicrobial activities, making them good candidates for critically needed new antibiotics. Sclerotia, the long-lived underground resistant mycelial structures of polypores such as Grifola umbellata and Wolfiporia cocos, also are good sources of secondary metabolites. Polysaccharide fractions of many polypores have shown remarkable anticancer effects in vivo through potentiation and stimulation of the entire immune system.
While a functional role for antibiotics can be assumed, a role for the compounds in the fungi that synthesize them, however, is unknown. Another neglected area of research in relation to the secondary metabolites of basidiomycetes is the difference in production of different compounds in different life history states, the mycelium (somatic assimilative state) and basidiocarp (reproductive state). They apparently are distinctive not only in function, but also in production of metabolites.
Of biologically active compounds from Basidiomycetes,
a number from Aphyllophorales (polypores) have found
their way to the market. In Japan, the polysaccharide anticancer drug PSK (Krestin) isolated from polypore Trametes
versicolor (as Coriolus versicolor) is on the market, together
with two other drugs from nonpolyporous wood-decaying
fungi: Lentinan (Enzolen) from Lentinus edodes (Shiitake),
and Schizophyllan (Sonifilan) from Schizophyllum commune. Several polysaccharide preparations from basidiomycetes, including polypores such as Grifola frondosa,
Ganoderma lucidum, and Trametes versicolor, are in clinical trials in the People's Republic of China. Extracts from
numerous Aphyllophorales are also available all over the
world as nutritional supplements or herbal remedies. There
is an intense interest in these so-called "mushroom nutriceuticals" by consumers. The market value of mushroom
dietary supplement products from Ganoderma lucidum
species alone worldwide is estimated to be $5-6 billion per
year, with $1.6 billion for the United States.110,111
The major research on isolation of pharmacologically active compounds from polypores, as well as other Basidiomycetes, comes from Germany, Japan, Korea, and the People's Republic of China, the countries with the historically best established tradition of the use of medicinal mushrooms. Unfortunately, the United States has been poorly represented in this research field. Considering, however, the leading role of the U.S. in the study of natural products worldwide, this gap could soon be filled. The large and well-preserved natural resources of North America, with a rich diversity of higher fungi, including polypores, makes a good base for more extensive research on the isolation and biological evaluation of natural products from mushrooms.
The author would like to thank his wife Krystyna for her patience, and Dr. William Day for his editorial work on the manuscript. Special thanks is owed to an anonymous reviewer for his outstanding contribution to the manuscript.
Dedicated to the late Dr. Monroe E. Wall and to Dr. Mansukh C. Wani
of Research Triangle Institute for their pioneering work on bioactive natural
products.
* Corresponding author. Tel: (662) 915-7290. Fax: (662) 915-6975. E-mail: jordan@olemiss.edu.
1. Hibbett, D. S.; Thorn, R. G. Basidiomycota: Homobasidiomycetes. Vol. VII, Part B (Mycota); McLaughlin, D. J., McLaughlin, E. G., Lempke, P. E., Eds.; Springer: New York, 2001; pp 121-168.
2. Gilbertson, R. L.; Ryvarden, L. North American Polypores; Fungiflora: Oslo, 1986 and 1987; Vols. 1 and 2.
3. Wasser, S. P. HerbalGram 2002, 56, 29-33.
4. Stamets, P. HerbalGram 2002, 54, 28-33.
5. Stamets, P. HerbalGram 2001, 51, 24, 27.
6. Reshetnikow, S. V.; Wasser, S. P.; Tan. K. K. Int. J. Med. Mushrooms
2001, 3, 361-394.
7. Abraham, W.-R. Curr. Med. Chem. 2001, 8, 583-606.
8. Brandt, C. R.; Piraino, F. Rec. Res. Dev. Antimicrob. Agents Chemother. 2000, 4, 11-26.
9. Wasser, S. P.; Weis, A. L. Crit. Rev. Immunol. 1999, 19, 65-96.
10. Wasser, S. P.; Weis, A. L. Int. J. Med. Mushrooms 1999, 1, 31-62.
11. Wasser, S. P.; Weis, A. L. Int. J. Med. Mushrooms 1999, 1, 351-370.
12. Lorenzen, K.; Anke, T. Curr. Org. Chem. 1998, 2, 329-364.
13. Anke, T. In Progress in Industrial Microbiology. Vol. 27. Bioactive Metabolites from Microorganisms; Bushell, M. E., Grafe, U., Eds.; Elsevier: Amsterdam, 1989; pp 51-66.
14. Suay, I.; Arenal, F.; Asenio, F. J.; Basilio, A.; Cabello, M. A.; Diez,
M. T.; Garcia, J. B.; Gonzalez del Val, A.; Gorrochategui, J.; Hernandez, P.; Pelaez, F.; Vicente, M. F. Antonie van Leeuwenhoek 2000,
78, 129-139.
15. Roussel, B.; Rapier, S.; Charlot, C.; Masson, C.-I.; Boutie, P. Rev. Hist.
Pharm. (Paris) 2002, 50, 599-614.
16. Peintner, U.; Poder, R.; Pumpel, T. Mycol. Res. 1998, 102, 1153-1162.
17. Mothana, R. A. A.; Jansen, R.; Juelich, W.-D.; Lindequist, U. J. Nat.
Prod. 2000, 63, 416-418.
18. Nakajima, S.; Kawai, K.; Yamada, S.; Sawai, Y. Agric. Biol. Chem.
1976, 40, 811-812.
19. Giannetti, B. M.; Steglich, W.; Quack, W.; Anke, T.; Oberwinkler, F.
Z. Naturforsch. C., J. Biosci. 1978, 33C, 807-816.
20. Quack, W.; Anke, T.; Oberwinkler, F.; Gianetti, B. M.; Steglich, W.
J. Antibiot. 1978, 31, 737-741.
21. Abate, D.; Abraham, W.-R. J. Antibiot. 1994, 47, 1348-1350.
22. Kupka, J.; Anke, T.; Giannetti, B. M.; Steglich, W. Arch. Microbiol.
1981, 130, 223-227.
23. Mellows, G.; Mantle, P. G.; Feline, T. C.; Williams, D. J. Phytochemistry 1973, 12, 2717-2720.
24. Mantle, P. G.; Mellows, G. Trans. Brit. Mycol. Soc. 1973, 61, 513-519.
25. Takeuchi, T.; Iinuma, H.; Iwanaga, J.; Takahashi, S.; Takita, T.;
Umezawa, H. J. Antibiot. 1969, 22, 215-217.
26. Takeuchi T.; Takahashi, S.; Iinuma, H.; Umezawa, H. J. Antibiot.
1971, 24, 631-635.
27. Lauer, U.; Anke, T.; Sheldrick, W. S.; Scherer, A.; Steglich, W. J.
Antibiot. 1989, 42, 875-882.
28. Smania, A., Jr.; Delle Monache, F.; Smania, E. F. A.; Cuneo, S. R.
Int. J. Med. Mushrooms 1999, 1, 325-330.
29. Keller, A. C.; Maillard, M. P.; Hostettmann, K. Phytochemistry 1996,
41, 1041-1046.
30. Anke, T.; Werle, A.; Zapf, S.; Velten, R.; Steglich, W. J. Antibiot. 1995,
48, 725-726.
31. Clough, J. M. Nat. Prod. Rep. 1993, 10, 565-574.
32. DeJong, E.; Field, J.; Spinnler, H. E.; Wijnberg, J. B. P. A.; DeBont,
J. A. M. Appl. Environ. Microbiol. 1994, 60, 264-270.
33. Robbins, W. J.; Kavanagh, F.; Hervey, A. Proc. Natl. Acad. Sci. U.S.A.
1947, 33, 176-182.
34. Nair, M. S. R.; Anchel, M. Tetrahedron Lett. 1975, 2641-2642.
35. Nair, M. S. R.; Anchel, M. Phytochemistry 1977, 16, 390-392.
36. Anke, T.; Giannetti, B. M.; Steglich, W. Z. Naturforsch. 1982,
37c,1-4.
37. Smania, E. F. A.; Smania, A., Jr.; Loguercio-Leite, C.; Gil, M. L. J.
Chem. Technol. Biotech. 1997, 70, 57-59.
38. Smania, E. F. A.; Smania, A., Jr.; Loguercio-Leite, C. Rev. Microbiol.
1998, 29, 317-320.
39. Deol, B. S.; Ridley, D. D.; Singh, P. Aust. J. Chem. 1978, 31, 1397-1399.
40. Morrison, E.; Kosiak, B.; Ritieni, A.; Aastveit, A. H.; Uhlig, S.;
Bernhoft, A. J. Agric. Food Chem. 2002, 50, 3070-3075.
41. Saito, H.; Tomioka, H.; Sato, K. J. Gen. Microbiol. 1988, 134, 1029-1035.
42. Tochikura, T. S.; Nakashima, H.; Hirose, K.; Yamamoto, N. Biochem.
Biophys. Res. Commun. 1987, 148, 726-733.
43. Tochikura, T. S.; Nakashima, H.; Yamamoto, N. J. Acquired Immun.
Defic. Syndr. 1989, 2, 441-447.
44. Hirose, K.; Hakozaki, M.; Kakuchi, J.; Matsunaga, K.; Yoshikumi,
C.; Takahashi, M.; Tochikura, T. S.; Yamamoto, N. Biochem. Biophys.
Res. Commun. 1987, 149, 562-567.
45. Okada, M.; Minamishima, Y. Microb. Immunol. 1987, 31, 45-57.
46. Colins, R. A.; Ng, T. B. Life Sci. 1997, 60, PL383-PL387.
47. Ng, T. B. Gen. Pharmacol. 1998, 30, 1-4.
48. Eo, S. K.; Kim, Y. S.; Oh, K. W.; Lee, C. K.; Lee, Y. N.; Han, S. S.
Arch. Pharm. Res. 2001, 24, 74-78.
49. Walder, R.; Kalvatchev, Z.; Garzaro, D.; Barrios, M. Acta Cient.
Venezolana 1995, 46, 110-114.
50. Ichimura, T.; Watanabe, O.; Maruyama, S. Biosci. Biotechnol. Biochem. 1998, 62, 575-577.
51. Awadh Ali, N. A.; Mothana, R. A. A.; Lesnau, A.; Pilgrim, H.;
Lindequist, U. Fitoterapia 2003, 74, 483-485.
52. Aoki, M.; Tan, M.; Fukushima, A.; Hieda, T.; Kubu, S.; Takabayashi,
M.; Ono, K.; Mikami, Y. Biosci. Biotech. Biochem. 1993, 57, 278-282.
53. Min, B.-S.; Nakamura, N.; Miyashiro, H.; Bae, K.-W.; Hattori, M.
Chem. Pharm. Bull. 1998, 46, 1607-1612.
54. El-Mekkawy, S.; Meselhy, M. R.; Nakamura, N.; Tezuka, Y.; Hattori,
M.; Kakiuchi, N.; Shimotohno, K.; Kawahata, T.; Otake, T. Phytochemistry 1998, 49, 1651-1657.
55. Mothana, R. A. A.; Awadh Ali, N. A.; Jansen, R.; Wegner, U.; Mentel,
R.; Lindequist, U. Fitoterapia 2003, 74, 177-180.
56. Mizuno, T. Int. J. Med. Mushrooms 1999, 1, 9-29.
57. Mizuno, T.; Saito, H.; Nishitoba, T.; Kawagishi, H. Food Rev. Int.
1995, 11, 23-61.
58. Sontag, B.; Arnold, N.; Steglich, W.; Anke, T. J. Nat. Prod. 1999, 62,
1425-1426.
59. Yoshikawa, K.; Bando, S.; Arihara, S.; Matsumura, E.; Katayama,
S. Chem. Pharm. Bull. 2001, 49, 327-329.
60. McMorris, T. C.; Anchel, M. Can. J. Chem. 1964, 42, 1595-1598.
61. Liberra, K.; Jansen, R.; Wegner, U.; Lindequist, U. Pharmazie 1995,
50, 370-371.
62. Ishizuka, M.; Iinuma, H.; Takeuchi, T.; Umezawa, H. J. Antibiot.
1972, 25, 320-321.
63. Ishizuka, M.; Takeuchi, T.; Umezawa, H. J. Antibiot. 1981, 34, 95-102.
64. Lorenzen, K.; Anke, T.; Anders, U.; Hindermayr, H.; Hansske, F. Z.
Naturforsch. C, J. Biosci. 1994, 49, 132-138.
65. Ohsawa, T.; Yukawa, M.; Takao, C.; Murayama, M.; Bando, H. Chem.
Pharm. Bull. 1992, 40, 143-147.
66. Valisolalao, J., Luu, B.; Ourisson, G. Tetrahedron 1983, 39, 2779-2785.
67. Chen, C.-H.; Yang, S.-W.; Shen, Y.-C. J. Nat. Prod. 1995, 58, 1655-1661.
68. Tie, Z.; Huang, X. Dictionary of Traditional Chinese Medicine; The Commercial Press Ltd.: Hong Kong, 1988; p 201.
69. Wu, T.-S.; Shi, L.-S.; Kuo, S.-C. J. Nat. Prod. 2001, 64, 1121-1122.
70. Gao, J.-J.; Min, B.-S.; Ahn, E.-M.; Nakamura, N.; Lee, H.-K.; Hattori,
M. Chem. Pharm. Bull. 2002, 50, 837-840.
71. Ukiya, M.; Akihisa, T.; Tokuda, H.; Hirano, M.; Oshikubo, M.;
Nobokuni, Y.; Kimura, Y.; Tai, T.; Kondo, S.; Nishino, H. J. Nat. Prod.
2002, 65, 462-465.
72. Hobbs, C. Medicinal Mushrooms. An Exploration of Tradition, Healing and Culture; Botanica Press: Santa Cruz, CA, 1995.
73. Ikekawa, T.; Nakanishi, M.; Uehara, N.; Chihara, G.; Fukuoka, F.
Cancer Res. 1969, 29, 734-735.
74. Mizuno, T. Food Rev. Int. 1995, 11, 129-133.
75. Yamada, H.; Kawaguchi, N.; Ohmori, T.; Takeshita, Y.; Taneya, S.;
Miyazaki, T. Carbohydr. Res. 1984, 125, 107-115.
76. Misaki, A.; Kakuta, M.; Sasaki, T.; Tanaka, M.; Miyaji, H. Carbohydr.
Res. 1981, 92, 115-129.
77. Ueno, Y.; Abe, M.; Yamauchi, R.; Kato, K. Carbohydr. Res. 1980, 87,
257-264.
78. Inoue, Y.; Chujo, R. Carbohydr. Res. 1977, 56, 351-355.
79. Usui, T.; Iwasaki, Y.; Mizuno, T.; Tanaka, M.; Shinkai, K.; Arakawa,
M. Carbohydr. Res. 1983, 115, 273-280.
80. Deslandes, Y.; Marchessault, R. H.; Sarko, A. Macromolecules 1980,
13, 1466-1471.
81. Saito, H.; Ohki, T.; Yoshioka, Y.; Fukuoka, F. FEBS Lett. 1976, 68,
15-18.
82. Yoshioka, Y.; Uehara, N.; Saito, H. Chem. Pharm. Bull. 1992, 40,
1221-1226.
83. Sugiura, M.; Ohno, H.; Kunihisa, M.; Hirata, F.; Ito, H. Jpn. J.
Pharmacol. 1980, 30, 503-513.
84. Mizuno, T.; Ando, M.; Sugie, R.; Ito, H.; Shimura, K.; Sumiya, T.;
Matsuura, A. Biosci. Biotech. Biochem. 1992, 56, 34-41.
85. Mizuno, T.; Sugiyama, K. Food Rev. Int. 1995, 11, 179-184.
86. Usui, T.; Iwasaki, Y.; Mizuno, T. Carbohydr. Res. 1981, 92, 109-120.
87. Tsukagoshi, S.; Hashimoto, Y.; Fujii, G.; Kobayashi, H.; Nomoto, K.;
Orita, K. Cancer Treat. Rev. 1984, 2, 131-155.
88. Yunoki, S.; Tanaka, N.; Hizuta, A.; Orita, K. Int. J. Immunopharmacol. 1994, 16, 123-130.
89. Kobayashi, Y.; Kariya, K.; Saigenji, K.; Nakamura, K. Cancer Biother.
1994, 9, 351-358.
90. Kobayashi H.; Matsunaga, K.; Oguchi, Y. Cancer Epidemiol. Biomarkers Prev. 1995, 4, 275-281.
91. Lu, W.; Adachi, I.; Kano, K.; Yasuta, A.; Toriizuka, K.; Ueno, M.;
Horikoshi, I. Chem. Pharm. Bull. 1985, 33, 5083-5087.
92. Su, C.-Y.; Shiao, M.-S.; Wang, C.-T. Thrombosis Res. 2000, 99, 135-145.
93. Hirotani, M.; O'Reilly, J.; Donnelly, D. M. X.; Polonsky, J. Tetrahedron
Lett. 1977, 651-652.
94. Kis, Z.; Closse, A.; Sigg, H. P.; Hruban, L.; Snatzke, G. Helv. Chim.
Acta 1970, 53, 1577-1599.
95. Erkel, G.; Anke, T.; Sterner, O. Biochem. Biophys. Res. Commun.
1996, 226, 214-221.
96. Weber, W.; Schu, P.; Anke, T.; Velten, R.; Steglich, W. J. Antibiot.
1994, 47, 1188-1194.
97. Kunimoto, T.; Umezawa, H. Biochim. Biophys. Acta 1973, 318, 78-90.
98. Atsumi, S.; Umezawa, K.; Iinuma, H.; Naganawa, H.; Nakamura, H.;
Iitaka, Y.; Takeuchi, T. J. Antibiot. 1990, 43, 49-53.
99. Weber, W.; Semar, M.; Anke, T.; Bross, M.; Steglich, W. Planta Med.
1992, 58, 56-59.
100. Dekermendjian, K.; Shan, R.; Nielsen, M.; Stadler, M.; Sterner, O.;
Witt, M. R. Eur. J. Med. Chem. 1997, 32, 351-356.
101. Szallasi, A.; Biro, T.; Szabo, T.; Modarres, S.; Petersen, M.; Klusch,
A.; Blumberg, P. M.; Krause, J. E.; Sterner, O. Br. J. Pharmacol. 1999,
126, 1351-1358.
102. Liu, J. Heterocycles 2002, 57, 157-167.
103. Appleton, R. E.; Jan, J. E.; Kroeger, P. D. Can. Med. Assoc. J. 1988,
139, 48-49.
104. Sato, M.; Tai, T.; Nunoura, Y.; Yajima, Y.; Kawashima, S.; Tanaka, K. Biol. Pharm. Bull. 2002, 25